AR109080A1 - Formas de sal de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)1h-imidazol-2-carboxamida - Google Patents
Formas de sal de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)1h-imidazol-2-carboxamidaInfo
- Publication number
- AR109080A1 AR109080A1 ARP170101992A ARP170101992A AR109080A1 AR 109080 A1 AR109080 A1 AR 109080A1 AR P170101992 A ARP170101992 A AR P170101992A AR P170101992 A ARP170101992 A AR P170101992A AR 109080 A1 AR109080 A1 AR 109080A1
- Authority
- AR
- Argentina
- Prior art keywords
- salt
- compound
- piran
- imidazol
- tetrametiltetrahidro
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229940126062 Compound A Drugs 0.000 abstract 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- -1 4,4-dimethylcyclohex-1-en-1-yl Chemical group 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract 1
- 125000005490 tosylate group Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Una forma de sal farmacéuticamente aceptable de 4-ciano-N-[2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2H-piran-4-il)piridin-3-il]-1H-imidazol-2-carboxamida (compuesto A) de fórmula (1), en donde la sal farmacéuticamente aceptable se selecciona del grupo que consiste en: sal de sulfato de Compuesto A; sal de fosfato de Compuesto A; sal de mesilato de Compuesto A; sal de tosilato de Compuesto A; y sal de besilato de Compuesto A.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363657P | 2016-07-18 | 2016-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109080A1 true AR109080A1 (es) | 2018-10-24 |
Family
ID=59631848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101992A AR109080A1 (es) | 2016-07-18 | 2017-07-17 | Formas de sal de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)1h-imidazol-2-carboxamida |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10266522B2 (es) |
| EP (1) | EP3484873A1 (es) |
| AR (1) | AR109080A1 (es) |
| MA (1) | MA45686A (es) |
| TW (1) | TW201811326A (es) |
| UY (1) | UY37339A (es) |
| WO (1) | WO2018017446A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6530173B2 (ja) * | 2014-10-27 | 2019-06-12 | 株式会社ブリヂストン | タイヤ |
| WO2018182527A1 (en) * | 2017-03-30 | 2018-10-04 | National University Of Singapore | Method for treating inflammatory complications in eye diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| US20140151258A1 (en) * | 2012-12-03 | 2014-06-05 | Cryovac, Inc. | Polymeric Films Comprising Biodegradable Polyester or Copolymer Thereof |
| HRP20180632T1 (hr) * | 2013-03-15 | 2018-06-01 | Janssen Pharmaceutica Nv | Supstituirani derivati piridina korisni kao inhibitori c-fms kinaze |
-
2017
- 2017-07-14 TW TW106123584A patent/TW201811326A/zh unknown
- 2017-07-17 WO PCT/US2017/042312 patent/WO2018017446A1/en not_active Ceased
- 2017-07-17 EP EP17752512.8A patent/EP3484873A1/en not_active Withdrawn
- 2017-07-17 MA MA045686A patent/MA45686A/fr unknown
- 2017-07-17 US US15/651,829 patent/US10266522B2/en active Active
- 2017-07-17 AR ARP170101992A patent/AR109080A1/es not_active Application Discontinuation
- 2017-07-19 UY UY0001037339A patent/UY37339A/es unknown
-
2019
- 2019-02-28 US US16/289,280 patent/US10562892B2/en active Active
-
2020
- 2020-01-08 US US16/737,273 patent/US10858348B2/en active Active
- 2020-11-05 US US17/090,548 patent/US20210053951A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3484873A1 (en) | 2019-05-22 |
| US10858348B2 (en) | 2020-12-08 |
| UY37339A (es) | 2018-01-31 |
| US20200140421A1 (en) | 2020-05-07 |
| MA45686A (fr) | 2019-05-22 |
| TW201811326A (zh) | 2018-04-01 |
| US20210053951A1 (en) | 2021-02-25 |
| US20190194175A1 (en) | 2019-06-27 |
| US20180016264A1 (en) | 2018-01-18 |
| WO2018017446A1 (en) | 2018-01-25 |
| US10266522B2 (en) | 2019-04-23 |
| US10562892B2 (en) | 2020-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
| UY37927A (es) | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| MA53675A (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret | |
| IL286912A (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| EP3706749A4 (en) | MACROCYCLIC COMPOUNDS AS TRK CINEMA INHIBITORS AND THEIR USES | |
| CY1119678T1 (el) | Πυριμιδινονες ως αναστολεις τελεστη χια | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| CO2017006099A2 (es) | Formas sólidas de un inhibidor ask1 | |
| AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| UY36684A (es) | Agonistas de triazol del receptor apj | |
| CO2017000064A2 (es) | Compuestos de [1,2,4]triazol sustituido | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| CO2019005165A2 (es) | Compuesto de piridona como inhibidor de c-met | |
| MA43021A (fr) | Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1 | |
| AR094959A1 (es) | Compuestos de imidazo piridina | |
| DK3160958T3 (da) | Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid | |
| MX382019B (es) | Sal de un compuesto de pirimido [6,1-a]isoquinolin-4-ona. | |
| EP3548031A4 (en) | TETRACYCLIC HETEROCYCLENE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | |
| MX388612B (es) | Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos. | |
| EP3446828A4 (en) | WORKING CENTER | |
| CL2018000290A1 (es) | Antagonistas del receptor de cgrp | |
| MX2018008966A (es) | Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |